tural requirements for the transport of glucose by intestine and kidney are presumed similar.
Increased attention has recently been directed to quantifying rates of glucose transport into tissues and organs, particularly by positron emission tomography (PET), using glucose analogs as tracers. For example, [ 18 F]2-deoxy-2-fluoro-D-glucose (2 18 FDG) was used in a PET dynamic study to estimate the effect of insulin on the transport of glucose across the bloodbrain barrier (12) and on glucose transport into muscle in obesity and diabetes (34) . That 2-fluoro-2-deoxy-D-glucose (2FDG) is phosphorylated as well as transported must be taken into account in estimating the transport parameters.
Scanning with 2 18 FDG has also become the preferred diagnostic imaging modality for a variety of human cancers. However, 2 18 FDG is not handled by cells precisely as glucose (10) . Thus, accumulation of 18 F activity in urine, because of 2FDG's limited transport by renal tubules, can interfere with visualization of pelvic and sometimes abdominal abnormalities (20, 30) . For better visualization, PET centers sometimes dilute or remove by catheter bladder contents (21) .
Despite the very short half-life of 11 C, [ 11 C]3OMG has been used to measure changes in brain glucose metabolism during hypoglycemia (2) , [ 11 C]3OMG and [ 14 C]3OMG to examine rates of glucose transport in muscle (6, 24) , and [ 11 C]methyl-D-glucoside to trace glucose transport in kidney (7) . [ 123 I]6-deoxy-6-iodo-D-glucose (6 123 IDG) was also recently proposed as a possible tracer (13) . It was reported to be responsive to insulin in in vitro preparations, although not in isolated rat heart, and able to detect a defect in glucose transport in diabetic mice (25) , although not in diabetic rats (17) . Additionally, 6 123 IDG was excreted in large amounts into the bladder within minutes after injection (17) . Since intestinal and renal transport likely have similar structural specificity, and 6-iodo-6-deoxygalactose is not transported by intestine (10, 35) , 6 123 IDG would not be expected to be transported by the proximal tubules.
Studies suggest that 6-fluoro-6-deoxy-D-glucose (6FDG), which has no hydroxyl at its carbon 6, and therefore cannot be phosphorylated, may be transported as is glucose (3) (4) (5) . Thus, 6FDG is actively transported by intestinal sacs of hamsters (35) . It competitively inhibits fermentation of glucose by intact yeast, but not yeast extracts (4) . Kinetic studies support 6FDG and 2DG competing with glucose at the same transport site and 6FDG not affecting any metabolic pathway within the yeast cell (5) .
We now report studies intended to help assess 6FDG's potential use as a tracer of glucose transport. To determine whether 6FDG is transported via facilitated diffusion pathways, the uptake of 6FDG was compared with that of 3OMG in Clone 9 cells that express glucose transporter 1 (GLUT1) and in 3T3-L1 adipocytes which express GLUT1 and GLUT4 (29) . 3OMG, commonly used in glucose transport assays, is transported but not phosphorylated. As a further test of whether 6FDG uptake is mediated by the GLUTs, its uptake with and without cytochalasin B (CB), a specific inhibitor of the GLUTs, was measured in both cell types under basal and stimulated conditions. Furthermore, 6 18 FDG uptake, in the absence and presence of phlorizin, an inhibitor of sodiumdependent glucose transport, and compared with 2 18 FDG uptake, was imaged by PET in rats.
MATERIALS AND METHODS
Radioactive glucose analogs. [1- 3 H]3OMG, specific activity 6.9 Ci/mmol, was purchased from NEN Life Science Products (Boston, MA). [1- 3 H]Glucose, specific activity 20 Ci/mmol, purchased from Moravek Biochem (Brea, CA), was converted on a microscale to [1- 3 H]6FDG (3). The tosyl group in the intermediate was replaced by fluoride ion using tetrabutyl ammonium fluoride, and then the isopropylidene blocking group was removed by acid hydrolysis. The [1- 3 H]6FDG was purified by descending paper chromatography using a butanol-acetic acid water system (23) . Glucose was well separated from the 6FDG, the mobility of which was established using guide spots of 6FDG purchased from Sigma Chemical (St. Louis, MO). The 6FDG eluted from the paper was further purified by HPLC using a Bio-Rad HPX-87P column (Bio-Rad Laboratories, Hercules, CA) with water at 80°C as solvent, giving a single radioactive peak with a specific activity of 0.5 Ci/mol. Glucose oxidase oxidized 6FDG at ϳ6% the rate of glucose assayed using a YSI 2300 glucose analyzer (Yellow Springs, OH). 6 18 FDG was prepared as we described elsewhere (22) .
Clone 9 cell culture. Clone 9 cells, subcultured in 60-mm culture dishes at a dilution of 1:6 in Dulbeco's Modified Eagle Medium (DMEM) containing 10% calf serum as previously described (18, 29) , were utilized between passages 27 and 55. Upon confluence and prior to study, the medium was replaced with medium devoid of serum for 24 h. Sodium azide (5 mM) or diluent were added to the cells 90 min prior to measurement of glucose transport.
3T3-L1 fibroblasts culture and differentiation. 3T3-L1 fibroblasts were also cultured as previously described (26) . Briefly, 3T3-L1 fibroblasts were cultured in DMEM (25 mM glucose) with 10% fetal bovine serum (FBS) for 4 days and then cultured in DMEM-FBS containing 1.7 M insulin, 0.25 M dexamethasone, and 0.5 mM 3-isobutyl-1-methylxanthine for 4 days to initiate differentiation. The medium was then changed to DMEM-FBS containing insulin alone, cultured for 3 more days and then changed to DMEM-FBS alone for 2-3 days. Under these conditions, Ͼ95% of the cell population exhibited the morphological characteristics of adipocytes. For uptake experiments, 3T3-L1 adipocytes were differentiated in 24-well plates, serum starved for 4 h, washed twice, and then incubated for 30 min in glucose-free DMEM. The 3T3-L1 adipocytes were then incubated with or without 10 nM insulin for 20 min.
Measurement of [ 3 H]3OMG and [ 3 H]6FDG uptake.
To measure glucose analog uptake, cells were incubated, as previously described (11), for 90 s in an uptake medium consisting of 0.5-1 ml of 3 H]6FDG, in the presence or absence of 50 M CB. Uptake was terminated by removal of the medium followed by five rapid washes with ice-cold phosphatebuffered saline containing 0.1 mM phloretin. Cells were harvested in 0.5 to 1 ml of water, and their protein content was determined by a modification of the method of Lowry using a test kit manufactured by Bio-Rad Laboratories. Their radioactivity content was determined by scintillation spectrometry. CB-inhibitable 3OMG and 6FDG uptake, assayed in parallel, were calculated as the difference between the mean uptake in each of replicate plates or wells in the absence (Ϫ) of CB and presence (ϩ) of CB (11 PET scanning. Male rats of the Sprague-Dawley strain, weighing 150 -300 g, were fasted overnight. A 30-gauge catheter was inserted into a tail vein of the rat. It was anesthetized with 2% isoflurane, taped to a plastic slab, and transported to a small animal PET scanner (Micro-PET R4 Siemens, formerly Concorde; Micro Systems, Knoxville, TN). Anesthesia was maintained at an isoflurane concentration of 1.5%. A three-part attenuation scan was done, with each part covering an 8-cm field of view and 7 min in length, to traverse the entire rat. The three parts were combined to create a whole body attenuation scan. The emission scan protocol that was used was for continuous bed motion at a speed of 16 s/pass; the scan was 60 min in duration. Synchronous with the emission scan (time 0), 6 18 FDG or 2 18 FDG, 0.5-1.0 mCi depending upon rat weight, was injected via catheter. The rat after the scan was returned to its cage to recover from the anesthesia. Eight rats were scanned with 6 18 FDG, six of which were scanned with, as well as without, phlorizin administration. Four rats were scanned with 2 18 FDG, all with and without phlorizin. Rats were randomly selected to receive phlorizin in their first or second scan. The two scans were performed Ն36 h apart. Phlorizin was injected intraperitoneally in 0.44 ml of saline at a concentration of 0.8 mg/kg 1 h before the transmission scan. During the emission scan the rats were infused intravenously with phlorizin at that same concentration at a rate of 1.5 ml/h. All images were reconstructed by iterative ordered subsets expectation maximization methods (14) . Volumes of interest were drawn on the bladder, brain, heart, left and right kidney, and liver for each rat. ASIpro VM microPET Data Analysis software (Concorde Microsystems) was used to quantitatively reconstruct and analyze the images. The tissue time activity curves (TTACs) were decay corrected, normalized by weight and dose, and expressed as 18 F activity concentrations in Ci/cc per Ci/g.
Statistical analysis. Uptakes in the cell incubation are presented as means Ϯ SE. A paired t-test was used to compare differences in uptakes. P values were obtained from the corresponding t values. The TTACs obtained on PET scanning were compared statistically in two ways. The activity concentrations from the last two frames in each scan, the last 10 min of scanning, were averaged, and those averages, taken as a measure of the end activity concentrations, were analyzed for significant differences. The area under the curve (AUC) for each TTAC, over the 60 min of scanning, except for the first 5 min, taken as the measure of the total activity concentrations, was also analyzed for significant differences. The AUC was estimated using the trapezoidal method in Matlab software (Mathworks, Natick, MA). Paired Figure 1 depicts the uptake of 3OMG and 6FDG in 3T3-L1 adipocytes under basal conditions and following 20 min of incubation in the presence of 10 nM insulin in both the absence and presence of CB. Under basal conditions, CB inhibited glucose transported, measured using 3OMG by 75% and using 6FDG by 76%. In the presence of insulin, CB inhibited uptake by 74% using 3OMG and by 78% using 6FDG. The stimulation by insulin of GLUT-mediated glucose transport was measured as 1.5-fold using 3OMG (basal vs. insulin, P ϭ 0.05), not different from the 1.6-fold stimulation measured using 6FDG (basal vs. insulin, P Ͻ 0.01). Figure 2 summarizes the results for the experiments performed with Clone 9 cells under basal conditions and following 90 min of exposure to 5 mM sodium azide. The uptake of 3OMG was inhibited by 58% and 6FDG by 81%, under basal conditions, and 3OMG by 84% and 6FDG by 93% in the presence of azide. The 4.3-fold stimulation of CB-inhibitable glucose transport measured using 3OMG was not different from the 3.7-fold stimulation measured using 6FDG (basal vs. azide, P Ͻ 0.001). Figure 3 presents images from two coronal slices and one sagittal slice, representative of those seen in the scannings. When 2 18 FDG was injected (Fig. 3A) without and ( Fig. 3B ) with phlorizin, 18 F was concentrated in heart, kidney, and bladder, with lesser amounts in brain and liver. Activity was prominent in the heart wall but not heart cavity. When 6 18 FDG was injected (Fig. 3C) without phlorizin, 18 F was distributed throughout those organs to a similar extent, except for its absence in bladder. On phlorizin injection, activity was in the bladder while appearing less prominent in brain and liver and more prominent in kidney. The TTACs on injections of 2 18 FDG and 6 18 FDG without and with phlorizin are shown (Figs. 4-7) for bladder, brain, heart, kidney (the average of the right and left kidney), and liver. The activity concentrations from which the curves were constructed are the means of the activity concentrations measured in the scans of the four rats given 2 18 FDG without and with phlorizin and the eight rats given 6 18 FDG, six without and with phlorizin. Within 5 min after 2 18 FDG was injected (Figs. 4 and 5) , 18 F activity spiked in kidney, i.e., there was an increase and then a decline, rapid and then gradual. Within a few minutes, activity appeared in the bladder, dramatically increasing over the remainder of the hour. There was also an early spike of activity in heart and liver. During the rest of the hour, activity increased in brain and heart but not liver. Among those three organs, activity concentration was highest in heart and least in liver.
When 6 18 FDG was injected (Figs. 6 and 7), early spikes in activity occurred in liver, heart, and kidney, as for 2 18 FDG, but they were not followed by increases in activity in any of the organs during the remainder of the hour, and the activity concentrations in them were not different. No 18 F was detected in the bladder on injecting 6 18 FDG in the absence of phlorizin, but on phlorizin injection activity rapidly increased in the bladder, as was the case for 2 18 FDG both with and without phlorizin. The end concentration activity of ϳ3 Ci/cc per uCi/g in all organs (Fig. 6 ) is in accord with 6 18 FDG being well distributed in body water by the end of the scan. The mean dose of 6 18 FDG injected was 530 Ci, and the mean weight of the rats was 226 g. Assuming the organs were 70% water, with a body water then of 0.7 ϫ 226 ϭ 158 cc, the activity expected would be 530/158 ϭ 3.2 Ci/cc per Ci/g. In accord with the increase in 18 F activity excretion on phlorizin administration, end activity concentrations in brain, heart, and liver were not different, but less (Fig. 7) , ϳ2 Ci/cc per Ci/g, in agreement with the 18 F again being distributable in body water. In comparing differences between Figs. 4 and 5 with those between Figs. 6 and 7, the effect of phlorizin on 6FDG is larger than that on 2FDG. However, both 2 18 FDG and 6 18 FDG with phlorizin have a greater excretion of the tracer, causing an overall drop of activity in tissues with phlorizin compared to without.
Figs. 8-11 provide a comparison of the TTACs for brain, heart, liver, and kidney. Where the P values for the difference between two curves are bracketed, the first P value is the comparison between the end concentration activities and the second between the AUCs. In brain (Fig. 8) , the end concentration and AUC were significantly greater with 2 18 FDG than with 6 18 FDG (P ϭ 0.04, 0.01). When phlorizin was given, 2 18 FDG activity was greater than 6 18 FDG activity (P ϭ 0.04, 0.01). The activity concentrations injecting 6 18 FDG were less with than without phlorizin (P ϭ 0.03, 0.01). In heart (Fig. 9) , concentrations were more when 2 18 FDG than 6 18 FDG was injected both without (P ϭ 0.001, 0.001) and with phlorizin (P ϭ 0.005, 0.02). Again, when 6 18 FDG was injected, concentrations declined when phlorizin was also given (P ϭ 0.003, 0.0004). For liver (Fig. 10) , end concentrations were less given 2 18 FDG than 6 18 FDG (P ϭ 0.009). End concentrations giving 6 18 FDG were again greater without than with phlorizin (P ϭ 0.001, 0.002), and that was also the case for 2 18 FDG (P ϭ 0. 03). In kidney (Fig. 11) , the AUC was significantly more for 2 18 FDG than 6 18 FDG without (P ϭ 0.02) but not with phlorizin. That is in accord with renal transport of 6 18 FDG being blocked by phlorizin and 2 18 FDG being poorly transported with and without phlorizin. Renal transport of 2 18 FDG appears lessened on phlorizin addition (P ϭ 0.04).
DISCUSSION
In the absence of azide, the inhibition by CB of 75% of 6FDG uptake in Clone 9 cells is good evidence for that uptake being mediated by GLUT1. Exposure to azide resulting in a severalfold stimulation of CB-inhibitable 6FDG uptake, similar to the result observed using 3OMG as a control, is evidence for 6FDG transport in the cells being via a facilitative GLUT1 transporter. Inhibition by CB of 75% of the basal transport of 6FDG in 3T3-L1 adipocytes, and stimulation of that uptake by insulin, again a result paralleling that observed with 3OMG, is evidence that 6FDG is insulin responsive and provides further support for 6FDG being a valid tracer of glucose transport.
Wick et al. (33) concluded 6FDG was not responsive to insulin, but they concluded this using a fed rabbit preparation in which an insulin effect may have been masked. Thus, they noted the rapid uptake of 6FDG in the absence of added insulin. Drury and Wick (8) reported that 3OMG was also nonresponsive using that preparation, but we found that it was responsive (16) , and many investigators have also since found that to be so. The negligible renal excretion of 6FDG, except on administering phlorizin, an inhibitor of renal glucose transport, provides good evidence for the active transport of 6FDG by kidney tubules. That finding is in accord with 6FDG's active transport by intestine and contrasts with findings for 2DG and 2FDG.
The 18 F peaks in heart, liver, and kidney, shortly after the administrations of 6 18 FDG and 2 18 FDG, presumably reflect the period when 6 18 FDG and 2 18 FDG blood concentrations were highest in those organs, with the declines occurring as the sugars were distributed in body water. The spikes are most marked in heart, presumably because of the blood volume it contains, and most prolonged in the kidney because of urine formation and excretion. The areas under those peaks during the first 5 min of scanning, then differing among the organs, were excluded from the calculation of the AUC (see Statistical analysis) to obtain a better measure of the difference among the organs in the distribution of the 18 F after its entrance into the organ volume. The gradual increase in activity in brain and heart over the remaining hour on 2 18 FDG administration is in accord with a gradual accumulation of 2 18 FDG 6-phosphate in those organs. That is also in accord with 18 F concentrating in heart wall compared with cavity when 2 18 FDG, but not 6 18 FDG, was injected. Glucose-6-phosphatase, catalyzing the hydrolysis of the 6-phosphate, presumably prevented accumulation in liver.
The failure of 18 F from 6 18 FDG to accumulate during the period following the peaks is in accord with 6FDG not being converted to any significant extent to metabolite(s) retained in those organs but rather being distributed unchanged in body water. In accord with that is the apparent same constant activity in all of the organs (Figs. 6 and 7) . The lower activity in the heart, brain, and liver with time, when phlorizin was given along with 6 18 FDG, then reflects the excretion of the 6FDG into the bladder. The lowest retention of 18 F in the kidney occurring when 6FDG was given in the absence of phlorizin can be explained by 6 18 FDG then being reabsorbed by the proximal tubules and reentering the systemic circulation. The blocking of that reabsorption then explains the greater concentration of 18 F in kidney volume when phlorizin was given. The overall effect of phlorizin on 6 18 FDG, due to being well transported by kidney, is greater than that on 2 18 FDG. Moran et al. (21) provided evidence that, whereas 2DG is not actively transported by kidney, 2FDG is to some extent. That is in accord with the end concentration in kidney suggesting less transport when 2 18 FDG was injected with than without phlorizin (P ϭ 0.04).
Although 6FDG cannot be phosphorylated at its 6th position, there are reports suggesting that 6FDG can be metabolized in some manner, at least when given in substrate quantity. Serif and Wick (28) reported that inhibition of glucose utilization by kidney slices approached 100% at high concentrations of 2DG but only 40% at high concentrations of 6FDG. They suggested that 6FDG might inhibit a specific pathway of glucose oxidation or transport. Bessell et al. (1) reported that 6FDG inhibited the growth of a transplanted lymphoma in mice. 6-Deoxy-, 6-chloro-, and 6-bromodeoxyglucose and the corresponding galactose derivatives were without effect. The LD 50 of 6FDG was ϳ200 mg/kg and of 2FDG ϳ600 mg/kg. A single dose of 6FDG of 500 mg/kg ip in rats produced degeneration and necrosis of centrilobular hepatocytes in 24 -48 h with restitution to normal structure in 6 days. After injecting 1 g/kg, 6FDG's concentration in blood at 30 min was three times that of glucose.
Competitive inhibition of glucose transport was postulated to explain the cytotoxic effect of 6FDG, but a large dose of glucose before giving 6FDG did not alter the toxicity (1) . A toxic metabolite of the 6FDG was considered a possible explanation, but 6FDG was then known only to be a substrate for glucose dehydrogenase and at a very high K m (19) . A highly toxic compound, such as fluoroacetate, formed by some unknown metabolic pathway, was considered unlikely. A single dose of 6FDG (120 mg/kg) inhibited spermatogenesis in rats (9) . The rats became infertile, but most recovered. The testes hypotrophied, and tubules were damaged. Doses to 960 mg/kg did not affect fertility in female mice. Glycolysis in rat seminiferous tubules was inhibited by incubation with 10 mM 6FDG. 6FDG is reported to be a substrate for aldose reductase (27) as well as glucose dehydrogenase (19) . The polyol formed on reduction is a substrate for sorbitol dehydrogrenase (27) . However, the K m s are much higher for the reductase, as well as the dehydrogenase, than the concentrations of 6FDG experienced in our administrations.
Developing a tracer that solely follows glucose transport could create a significant opportunity in radiopharmaceutical research (10) . The dose 6 18 FDG needed in adult humans for PET may be expected to be in a range used for 2 18 FDG, i.e., between 5 and 10 mCi. With a specific activity of 200 -2,000 mCi/mol in its preparation (22) , the amount of 6FDG injected, including carrier, would be at most only about 10 g, also many magnitudes less than what LD 50 reports in mice of 200 mg/kg. A sugar whose kinetics trace solely glucose transport could aid in the understanding of the separate contributions of glucose transport, glucose phosphorylation, and the downstream pathways of phosphorylated glucose utilization in physiological and pathological states. 6FDG may fulfill that need, reflecting glucose transport not only in insulin-responsive tissues but also in nonresponsive tissues.
